Pre- Congress Workshops


14 APRIL 9:00 - 17:00 - FULL DAY WORKSHOPS



Anti-Infective Immunotherapies

Should there really be a distinction between passive and active immunization when responding to diseases and infections therapeutically?

Join this workshop to understand how anti-infective immunotherapies in anti-bacterial, anti-viral and anti-fungal treatments   are increasingly combined and the role of both passive and active immunization in future.


  • Dr Vu L. Truong , Founder, Chief Executive Officer, and Director, Aridis
  • Dr Timothy Cooke , CEO, NovaDigm, Therapeutics & Biotechnology Representative, US National Vaccine Advisory Committee
  • Arturo Casadevall , Chairman of Molecular Microbiology and Immunology, John Hopkins Bloomberg School of Public Health
  • Dr Javad Aman , President and CSO, Integrated BioTherapeutics, Inc
  • Larry Zeitlin , President, Mapp Biopharmaceutical, Inc. 
  • Dr Gerald Pier , Professor of Medicine (Microbiology and Immunobiology), Harvard Medical School
  • Mark Esser , Senior Director, Vaccines and Infectious diseases – Translational Medicine, Medimmune
  • Sumathi Nambiar , Director, Division of Anti-Infective Products, U.S. Food & Drug Administration



Market access & regulatory challenges in vaccines

The market access landscape for vaccines is more complex than most. Various obstacles are creating a disproportionate move away from investing in preventative interventions and vaccines. 

Learn how get optimal value for our vaccines and avoid the pit falls when launching a new vaccine.


  • Dr Arthur Reingold , Professor and Division Head Epidemiology, Former ACIP Member, UC Berkley School of Public Health
  • Dr David Salisbury , Former Director of Immunization, Department of Health UK, Associate Fellow, Centre on Global Health Security
  • Dr Bradford Gessner , Scientific Director and Chief Epidemiologist, AMP; Vice President, Global Medical Lead for Pneumococcal Vaccines, Pfizer Vaccines
  • Dr Katherine O’Brien , Executive Director of the International Vaccine Access Center, Professor, Global Disease Epidemiology and Control, Johns Hopkins Bloomberg School of Public Health
  • Dr James Wassil , Business Unit Lead, Vaccines, Global Health & Value, Pfizer



The role of vaccines in preventing outbreaks, through natural causes or biothreats

It only takes natural outbreaks and bioterrorism attacks like the Ebola and anthrax to highlight the danger and fragile balance we live in. To ensure global and international security , important decisions need to be made in stockpiling and prioritizing research efforts, however there is a lack of vaccine manufacturers producing these countermeasure treatments.

Participate in this workshop to understand the rationale for developers to produce these lower commercial interest vaccines, and the challenges/opportunities associated in working with the government.  


  • Col Matthew Hepburn , Program Manager, DARPA
  • Dr James Crowe , Director, Vanderbilt Vaccine Centre 
  • LTC Julie Ake , Walter Reed Institute 
  • Mike Watson , SVP Vaccine Partnerships & Health Impact, Moderna Therapeutics
  • Gerald Parker , Associate Dean, Global One Health
  • Dr David Hone , Chief Scientist, Vaccine and Therapeutics Division, JSTO, Defense Threat Reduction Agency (DTRA)
  • Michael Merchlibsky , Scientific Program Manager, BARDA, HHS BARDA 
  • Jason Roos , Deputy Program Executive Officer, JPM-MCS


Trials and tribulations of integrating adjuvants into your vaccine. What’s the value of current and new adjuvants? 


  • Arnaud Didierlaurent , Senior Director-Head of Adjuvant platform, GSK Vaccines
  • Dr Carl R. Alving , Emeritus Senior Scientist, Former Chief, Laboratory of Adjuvant & Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research
  • Dr Ofer Levy , Staff Physician & Principal Investigator, Director, Precision Vaccines Program
  • Dr Derek O'Hagan , Global Head of Discovery Support and New Technology, GSK Vaccines
  • Dr Darrell J. Irvine , Professor of Materials Science & Engineering and Biological Engineering, MIT
  • Randall Hyer , Vice President, Clinical Development and Medical Affairs, Dynavax
  • Dr Wolfgang Lietner , Chief, Innate Immunity Section, NIH   
  • Dr Bob Seder , Chief, Cellular Immunology Section, NIH





9:00 - 12:30pm


Emerging Tools – Paradigm shift in vaccine technologies 

New emerging tools in immunology have become a much-anticipated field over the years with increasingly more preclinical and clinical staged developments.

This workshop focuses on recent advances in systems biology, structural vaccinology, computational tools, artificial intelligence and machine learning - and their application in providing protection against infectious diseases to improve immunogenicity of vaccines and understanding the immune response.


  • Dr Bette Tina Marie Korber , Laboratory Fellow, Los Alamos National Laboratory  
  • Dr Galit Alter , Associate Professor in Medicine, Principle Investigator, Harvard Medical School
  • Steven Bosinger , Director Yerkes Nonhuman Primates Genomic Core, Assistant Professor, Emory School of Medicine Department of Pathology & Lab Medicine
  • Dr Rino Rappuoli , Chief Scientist, GSK Vaccines
  • Harry Kleanthous , Associate Vice President, Head of Discovery Research North America, Sanofi ​


9:00 – 12:30pm

This workshop will focus on the epidemiology, background medical need, advances in the research and development of therapeutic and prophylactic vaccines for HPV and EBV and challenges and considerations for each approach. 

  • Dr John Schiller , Deputy Chief, Laboratory of Cellular Oncology, NIH Distinguished Investigator, Head, Neoplastic Disease Section, National Cancer Institute, NIH
  • Dr Prakash Bhuyan , VP Clinical Development, Inovio
  • Dr Corey Casper , CMO, IDRI  
  • Dr Jeffrey Cohen , Chief, Laboratory of Infectious Diseases, Chief, Medical Virology Section, NIAID, NIH
  • Dr Graham Taylor , Senior Lecturer Tumor Immunology, Institute of Immunology and Immunotherapy, University of Birmingham​

1:30 – 5:00pm


The influence of the microbiome in vaccine response 

The importance of considering the whole microbiome—taking into account viruses, bacteria, fungi, and parasites , as potential modulators of immune responses, inflammation and drivers of heterogeneity in vaccine responses—is becoming increasingly evident.

Join this workshop to learn more about how we can use this information to create better vaccines


  • Mollie Roth , Executive Director, The Microbiome Coalition
  • Dr Mathew Henn , Seres Therapeutics, Executive VP, Microbiome R&D, Seres Therapeutics 
  • Dr Nikole Kimes , CSO, Siolta Therapeutics 
  • Dr Sonia Timberlake , VP Research, Finch Therapeutics
  • Dr Shahram Lavasani , Founder and CEO, ImmuneBiotech
  • Dr Jean-Pierre Routy , Professor of Medicine, McGill University Health Centre​

1:30 - 5:00pm


Approaches to establishing clinically relevant specifications for vaccine bioprocessing


  • Dr Basav Ghosh, , Senior Director, Manufacturing Sciences and Technology, Pfizer
  • Dr Bo Arve, Executive Director, BioPharmaceutical Sciences, Pfizer
  • Dr Willie Van, Chief, Laboratory of Bacterial Polysaccharides, FDA

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington


To Sponsor Or Exhibit

Marc Rhys-Evans
+44 20 7827 5945




To Register

Tayyab Abbasi
+44 20 7092 1210




Press Relations

Karina Kusova
+44 20 7092 1071